AstraZeneca Pharmaceuticals LP
NEWS
There continue to be studies and trials related to vaccines and drugs against COVID-19. Here’s a look.
In mid-March, more than a dozen countries suspended the deployment of the AstraZeneca-Oxford University vaccine after incidences of blood clots were reported.
In order to have full control of J&J’s product, the production of the AstraZeneca vaccine, which was being conducted at the same facility, will move elsewhere.
There was a fair amount of clinical trial news last week. Here’s a look.
The announcement by the NIAID, a part of the National Institutes of Health (NIH), is very unusual.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 23, 2021.
A giant in the world of oncology has fallen. José Baselga, whose research paved the way for new treatments in different types of cancer, died Sunday.
AstraZeneca reported that the U.S. Phase III trial of the vaccine, AZD1222, demonstrated an efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and hospitalization.
The results published in the NEJM state that pegcetacoplan met the study’s primary endpoint for efficacy, demonstrating an advantage over eculizumab with a statistically significant improvement in adjusted means of 3.8 g/dL of hemoglobin at week 16 (p<0.001). An impressive 85% of patients were transfusion free at 16 weeks, in contrast to only 15% of eculizumab-treated patients.
JOBS
IN THE PRESS